Takeda announced that zasocitinib, the TYK2 inhibitor it acquired in a $4 billion deal, met primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said the studies showed clinically meaningful skin clearance versus placebo and active comparator arms, and it plans regulatory submissions in 2026. TYK2 inhibitors target intracellular signaling in type‑2 and inflammatory pathways; Takeda positions zasocitinib as an oral alternative to injectables. The trials reported expected adverse events such as upper respiratory infections and acne; full safety tables will be presented at medical meetings. The readouts revive a high‑value acquisition rationale: Takeda acquired the asset from Nimbus and now expects zsocitinib to contribute materially to its dermatology franchise and broader immunology program if regulators concur.